More than 4,000 Attend World Congress

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

VANCOUVER, BC-More than 4,000 pain experts from all over the world attended the International Association for the Study of Pain (IASP) 8th World Congress on Pain, at the Vancouver Trade and Convention Centre.

VANCOUVER, BC-More than 4,000 pain experts from all over the worldattended the International Association for the Study of Pain (IASP)8th World Congress on Pain, at the Vancouver Trade and ConventionCentre.

"The Congress is an opportunity for pain researchers andclinicians to discuss the latest advances in the field,"said IASP president John D. Loeser, MD, of the University of Washington."It's only within the last 20 years that medical sciencehas developed advanced assessment tools and intervention strategiesto reduce pain and suffering," he said.

The 8th World Congress was dedicated to the memory of ProfessorJohn J. Bonica who pioneered the multi-disciplinary approach topain management with the establishment in 1961 of the Universityof Washington Multidisciplinary Pain Center.

Dr. Loeser is the Center's current director.

Recent Videos
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Two experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
7 experts are featured in this series.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Related Content